-
Mashup Score: 3Loader - 1 hour(s) ago
We have noticed an unusual activity from your IP 199.16.157.180 and blocked access to this
Source: CheckRare.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Data from the phase 1/2 eNRGy trial support the biologics license application for zenocutuzumab in NRG1-positive NSCLC and PDAC.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Learn about our metastatic breast cancer support and education at Dana-Farber Cancer Institute today.
Source: www.dana-farber.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0H-E-B | Curbside Pickup & Grocery Delivery | HEB.com - 1 hour(s) ago
No store does more than your H-E-B, where you’ll find savings on products you love, without compromise of convenience, quality or selection. Free Curbside!
Source: www.heb.comCategories: General Medicine News, Onc News and JournalsTweet-
Our friends @HEB are supporting our mission to #EndCancer. Through June 4, customers across Texas to round up their purchase to the nearest dollar or add a $1, $3, $5 or $10 donation to MD Anderson at registers, through https://t.co/hZmcXZzsrL or via the HEB curbside and delivery… https://t.co/vfuUsyEzLk https://t.co/4tw9vAWz6o
-
-
Mashup Score: 0For Detection of Measurable Residual Disease in Ovarian Cancer, Are Two Methods Better Than One? - 1 hour(s) ago
In patients with ovarian cancer, second-look surgery may find a role again. The evaluation of measurable residual disease (MRD) using second-look laparoscopy identified more women who had detectable M…
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Statin use and risks of breast cancer recurrence and mortality - 2 hour(s) ago
Cancer is an international interdisciplinary journal publishing articles on the latest clinical cancer research findings, spanning the breadth of oncology disciplines.
Categories: General Medicine News, Onc News and JournalsTweet-
Findings of this new study suggest that post-diagnosis statin use is associated with improved cancer-specific survival in women with #BreastCancer and should be confirmed in randomized trials of statin therapy in breast cancer patients. https://t.co/8h7WPVhfQl @OncoAlert #BCSM https://t.co/aUvD1ytBxc
-
-
Mashup Score: 4Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries - 2 hour(s) ago
CA: A Cancer Journal for Clinicians is ACS’ flagship clinical oncology journal publishing information about the prevention, early detection, and treatment of cancer.
Categories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Disparities in OncotypeDx Testing and Subsequent Chemotherapy Receipt by Geography and Socioeconomic Status - 2 hour(s) ago
AbstractBackground:. OncotypeDx is a prognostic and predictive genomic assay used in early-stage hormone receptor–positive, HER2− (HR+/HER2−) breast cancer. It is used to inform adjuvant chemotherapy decisions, but not all eligible women receive testing. We aimed to assess variation in testing by demographics and geography, and to determine whether testing was associated with chemotherapy.Methods:. For 1,615 women in the Carolina Breast Cancer Study with HR+/HER2−, Stage I–II tumors, we estimated prevalence differences (PD) and 95% confidence intervals (CI) for receipt of OncotypeDx genomic testing in association with and sociodemographic characteristics. We assessed associations between testing and chemotherapy receipt overall and by race. Finally, we calculated the proportion of eligible women receiving OncotypeDx by county-level rurality, census tract-level socioeconomic status, and Area Health Education Center regions.Results:. 38% (N = 609) of potentially eligible women were teste
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort - 2 hour(s) ago
Breast cancer (BC) is the second most common cancer that metastasizes to the brain. Particularly up to half of patients with human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (mBC) may develop brain metastases over the course of the disease. Nevertheless, little is known about the prevalence and the outcome of brain and leptomeningeal metastases (BLMM) in HER2-low BC. We compared the cumulative incidence of BLMM and associated outcomes among patients with HER2-low, HER2-negative (HER2−) and HER2+ mBC.
Source: www.esmoopen.comCategories: General Medicine News, Onc News and JournalsTweet-
Does HER2-low expression impact the incidence of brain metastases from breast cancer? In a large analysis from the ESME database, Dr. Epaillard et al. demonstrate similar incidence and outcomes of brain mets for HER2-low vs HER2-0 metastatic breast cancer. https://t.co/TkPr9yqiB8 https://t.co/v3axElp0zr
-
-
Mashup Score: 1
Treatment with acalabrutinib-based regimens led to long-term benefits in patients with higher-risk CLL, across all lines of therapy.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
Mathias Schmidt, PhD, President and Chief Executive Officer of JCR USA, describes their current clinical trials for patients with mucopolysaccharidosis #MPS I and II #CheckRare #RareDisease https://t.co/9onF5FlegI